BMY - Bristol-Myers Squibb Company
NYSE
->
Healthcare
->
Drug Manufacturers—General
New York,
United States
Type: Equity
BMY price evolution
BMY
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6293 | $9330 | $11464 | |
| Short term investments | $360 | $340 | $816 | |
| Net receivables | $14895 | $11423 | $10447 | $10921 |
| Inventory | $3332 | $3077 | $2985 | $2662 |
| Total current assets | $28075 | $26890 | $28669 | $31770 |
| Long term investments | $357 | $367 | $364 | |
| Property, plant & equipment | $8251 | $6845 | $6750 | $6646 |
| Goodwill & intangible assets | $51160 | $54498 | $48241 | |
| Total noncurrent assets | $67756 | $70362 | $63389 | |
| Total investments | $717 | $707 | $1180 | |
| Total assets | $93670 | $94646 | $99031 | $95159 |
| Current liabilities | ||||
| Accounts payable | $3469 | $3751 | $3539 | $3259 |
| Deferred revenue | ||||
| Short long term debt | $3531 | $6190 | $3119 | |
| Total current liabilities | $22638 | $23265 | $25822 | $22262 |
| Long term debt | $48674 | $48858 | $49487 | $36653 |
| Total noncurrent liabilities | $54312 | $56661 | $43412 | |
| Total debt | $52389 | $55677 | $39772 | |
| Total liabilities | $76528 | $77577 | $82483 | $65674 |
| Shareholders' equity | ||||
| Retained earnings | $16097 | $16103 | $15640 | $28766 |
| Other shareholder equity | -$1473 | -$1456 | -$1400 | -$1546 |
| Total shareholder equity | $17015 | $16490 | $29430 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $11464 | $9123 | $13979 | $14546 |
| Short term investments | $816 | $130 | $2987 | $1285 |
| Net receivables | $10921 | $9886 | $9369 | $8501 |
| Inventory | $2662 | $2339 | $2095 | $2074 |
| Total current assets | $31770 | $27273 | $33262 | $30192 |
| Long term investments | $364 | $433 | ||
| Property, plant & equipment | $6646 | $7475 | $6049 | $5886 |
| Goodwill & intangible assets | $48241 | $57008 | $63029 | $73790 |
| Total noncurrent assets | $63389 | $69547 | $76052 | $88289 |
| Total investments | $1180 | $130 | $2987 | $1718 |
| Total assets | $95159 | $96820 | $109314 | $118481 |
| Current liabilities | ||||
| Accounts payable | $3259 | $3040 | $2949 | $2713 |
| Deferred revenue | ||||
| Short long term debt | $3119 | $4264 | $4948 | $2340 |
| Total current liabilities | $22262 | $21890 | $21868 | $19080 |
| Long term debt | $36653 | $35056 | $39605 | $48336 |
| Total noncurrent liabilities | $43412 | $43812 | $51440 | $61519 |
| Total debt | $39772 | $39320 | $44553 | $50676 |
| Total liabilities | $65674 | $65759 | $73308 | $80599 |
| Shareholders' equity | ||||
| Retained earnings | $28766 | $25503 | $23820 | $21281 |
| Other shareholder equity | -$1546 | -$1281 | -$1268 | -$1839 |
| Total shareholder equity | $29430 | $31061 | $35946 | $37822 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11892 | $12201 | $11865 | $11477 |
| Cost of revenue | $3267 | $2932 | ||
| Gross Profit | $9036 | $8934 | $8933 | $8770 |
| Operating activities | ||||
| Research & development | $2899 | $2695 | ||
| Selling, general & administrative | $1928 | $2367 | ||
| Total operating expenses | $6271 | $7648 | $20449 | $6159 |
| Operating income | $1286 | -$11516 | ||
| Income from continuing operations | ||||
| EBIT | $1282 | -$11519 | ||
| Income tax expense | $461 | -$398 | $392 | -$88 |
| Interest expense | -$399 | -$118 | ||
| Net income | ||||
| Net income | $1211 | $1680 | -$11911 | $1762 |
| Income (for common shares) | $1680 | -$11911 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $45006 | $46159 | $46385 | $42518 |
| Cost of revenue | $10137 | $9940 | $11773 | |
| Gross Profit | $34488 | $36022 | $36445 | $30745 |
| Operating activities | ||||
| Research & development | $9509 | $11354 | $11143 | |
| Selling, general & administrative | $7814 | $7690 | $7661 | |
| Total operating expenses | $23582 | $28309 | $28347 | $37616 |
| Operating income | $7713 | $8098 | -$6871 | |
| Income from continuing operations | ||||
| EBIT | $7695 | $8078 | -$6891 | |
| Income tax expense | $400 | $1368 | $1084 | $2124 |
| Interest expense | -$877 | |||
| Net income | ||||
| Net income | $8025 | $6327 | $6994 | -$9015 |
| Income (for common shares) | $6327 | $6994 | -$9015 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $1680 | -$11911 | $1762 | |
| Operating activities | ||||
| Depreciation | $2596 | $2532 | $2464 | |
| Business acquisitions & disposals | -$1103 | -$19812 | -$340 | |
| Stock-based compensation | $125 | $133 | $127 | |
| Total cash flows from operations | $2326 | $2834 | $4252 | |
| Investing activities | ||||
| Capital expenditures | -$262 | -$284 | -$330 | |
| Investments | $46 | $478 | -$676 | |
| Total cash flows from investing | -$21156 | -$1319 | -$19618 | -$1346 |
| Financing activities | ||||
| Dividends paid | -$3645 | -$1217 | -$1212 | -$1160 |
| Sale and purchase of stock | -$6 | -$97 | $25 | |
| Net borrowings | -$2800 | $15953 | $2102 | |
| Total cash flows from financing | $6769 | -$4023 | $14644 | $967 |
| Effect of exchange rate | $10 | -$22 | -$45 | $78 |
| Change in cash and equivalents | -$3626 | -$3038 | -$2185 | $3951 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $8025 | $6327 | $6994 | -$9015 |
| Operating activities | ||||
| Depreciation | $9760 | $10276 | $10686 | $10380 |
| Business acquisitions & disposals | -$260 | -$2981 | -$862 | -$12214 |
| Stock-based compensation | $518 | $457 | $583 | $779 |
| Total cash flows from operations | $13860 | $13066 | $16207 | $14052 |
| Investing activities | ||||
| Capital expenditures | -$1209 | -$1118 | -$973 | -$753 |
| Investments | -$826 | $3037 | $1297 | $2108 |
| Total cash flows from investing | -$2295 | -$1062 | -$538 | -$10859 |
| Financing activities | ||||
| Dividends paid | -$4744 | -$4634 | -$4396 | -$4075 |
| Sale and purchase of stock | -$5128 | -$8001 | -$6287 | -$1546 |
| Net borrowings | $456 | -$5311 | -$6182 | $3928 |
| Total cash flows from financing | -$9416 | -$16962 | -$16224 | -$1151 |
| Effect of exchange rate | $45 | -$33 | -$102 | $111 |
| Change in cash and equivalents | $2194 | -$4991 | -$657 | $2153 |
News
Fundamentals
| Market cap | $112.15B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.03B |
| Revenue | $47.44B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$7.26B |
| Revenue Q/Q | 8.44% |
| Revenue Y/Y | 5.56% |
| P/E ratio | -15.45 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.36 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.58 |
|---|---|
| ROA | -7.59% |
| ROE | N/A |
| Debt/Equity | 2.23 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.24 |
| Quick ratio | 1.09 |